About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker DRTSW · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 12, 2026Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
NCT06910306 · Recurrent Glioblastoma, Recurrent Gliomas
Device :DaRT seeds
DRTS
Alpha Tau Medical Ltd.
Not applicableRecruiting20Nov 1, 2026Registry ↗
Oct 27, 2026Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metasta…
NCT06698458 · Pancreatic Cancer, Pancreatic Adenocarcinoma
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
DRTS
Alpha Tau Medical Ltd.
Not applicableActive, not recruiting50Oct 2026Registry ↗
Jul 15, 2026Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Pat…
NCT06615635 · Squamous Cell Carcinoma, Alpha Radiation
DaRT seeds
DRTS
Alpha Tau Medical Ltd.
Not applicableRecruiting28Dec 2026Registry ↗
Jun 24, 2026Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer
NCT06755359 · Pancreatic Cancer, Locally Advanced Pancreatic Cancer
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
DRTS
Alpha Tau Medical Ltd.
Not applicableRecruiting40Jan 2027Registry ↗
Jun 16, 2026Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prosta…
NCT06202248 · Non-metastatic Prostate Cancer, Locally Recurrent Prostate…
Experimental: DaRT seeds
DRTS
Alpha Tau Medical Ltd.
Not applicableRecruiting10Jun 2027Registry ↗
Jun 16, 2026Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanc…
NCT06026943 · Pancreatic Cancer, Unresectable Pancreatic Cancer
DaRT seeds insertion
DRTS
Alpha Tau Medical Ltd.
Not applicableRecruiting15Jan 2027Registry ↗
Jun 16, 2026Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases
NCT05829291 · Liver Metastases
Diffusing Alpha Radiation Emitters Therapy (DaRT)
DRTS
Alpha Tau Medical Ltd.
Not applicableRecruiting10Feb 2027Registry ↗
Jun 16, 2026Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors
NCT05781555 · Malignant Tumor
Experimental: DaRT seeds
DRTS
Alpha Tau Medical Ltd.
Not applicableRecruiting100Apr 2027Registry ↗
Jun 16, 2026Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Sa…
NCT05657743 · Pancreatic Cancer, Unresectable Pancreatic Cancer
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
DRTS
Alpha Tau Medical Ltd.
Not applicableRecruiting15Nov 2026Registry ↗
Jun 16, 2026Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer
NCT05632913 · Recurrent Lung Cancer, Lung Cancer
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
DRTS
Alpha Tau Medical Ltd.
Not applicableRecruiting10Feb 2027Registry ↗
Jun 16, 2026Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carci…
NCT05323253 · Recurrent Squamous Cell Carcinoma
DaRT seeds
DRTS
Alpha Tau Medical Ltd.
Not applicableActive, not recruiting86Apr 2027Registry ↗
Jun 16, 2026Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft…
NCT04534127 · Skin Cancer, Mucosal Neoplasm of Oral Cavity
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
DRTS
Alpha Tau Medical Ltd.
Not applicableRecruiting56Jan 1, 2027Registry ↗
Jun 16, 2026Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
NCT04068155 · Skin Cancer, Cutaneous Tumor
DaRT- Diffusing Alpha-emitters Radiation Therapy
DRTS
Alpha Tau Medical Ltd.
Not applicableRecruiting80Jan 2027Registry ↗
Apr 6, 2026Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer
NCT07290998 · Prostate Cancer, Recurrent Prostate Cancer
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
DRTS
Alpha Tau Medical Ltd.
Not applicableNot yet recruiting12May 2028Registry ↗
Apr 6, 2026Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment…
NCT05047094 · Head and Neck Squamous Cell Carcinoma, Skin Cancer
Diffusing Alpha Radiation Emitters Therapy (DaRT), Pembroli…
DRTS
Alpha Tau Medical Ltd.
Not applicableRecruiting48Dec 2026Registry ↗
Apr 6, 2026Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue…
NCT03737734 · Skin Cancer, Mucosal Neoplasm of Oral Cavity
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
DRTS
Alpha Tau Medical Ltd.
Not applicableActive, not recruiting30Dec 2026Registry ↗
Dec 8, 2025Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue…
NCT03886181 · Skin Cancer, Mucosal Neoplasm of Oral Cavity
Device: Radiation: Diffusing Alpha Radiation Emitters Thera…
DRTS
Alpha Tau Medical Ltd.
Not applicableTerminated2Oct 13, 2024Registry ↗
Dec 2, 2025Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With…
NCT04543903 · Prostate Adenocarcinoma
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
DRTS
Alpha Tau Medical Ltd.
Not applicableCompleted1Oct 1, 2025Registry ↗
Dec 2, 2025Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
NCT04540588 · Skin Cancer, Mucosal Neoplasm of Oral Cavity
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
DRTS
Alpha Tau Medical Ltd.
Not applicableCompleted2Dec 1, 2025Registry ↗
Dec 2, 2025Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer
NCT04002479 · Pancreatic Cancer, Unresectable Pancreatic Cancer
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
DRTS
Alpha Tau Medical Ltd.
Not applicableActive, not recruiting37Oct 2026Registry ↗
Dec 2, 2025Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft…
NCT03889899 · Skin Cancer, Mucosal Neoplasm of Oral Cavity
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
DRTS
Alpha Tau Medical Ltd.
Not applicableRecruiting30Jun 2026Registry ↗
Feb 7, 2025A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly…
NCT06202118 · Breast Cancer, Recurrent Breast Cancer
Diffusing Alpha Radiation Emitters Therapy (DaRT)
DRTS
Alpha Tau Medical Ltd.
Not applicableRecruiting10Jan 2026Registry ↗
May 17, 2024Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC
NCT05065346 · Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcin…
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT
DRTS
Alpha Tau Medical Ltd.
Not applicableUnknown79Dec 2025Registry ↗
Jan 31, 2024Alpha Radiation Emitters Device for the Treatment of Primary and Recurrent Squamous Cell Carcinoma…
NCT06202339 · Carcinoma of the Vulva, Recurrent Carcinoma of the Vulva
DaRT seeds
DRTS
Alpha Tau Medical Ltd.
Not applicableNot yet recruiting10Apr 2026Registry ↗
Jan 18, 2024Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With…
NCT03970967 · Breast Carcinoma, Metastatic Breast Cancer
Device: Radiation: Diffusing Alpha Radiation Emitters Thera…
DRTS
Alpha Tau Medical Ltd.
Not applicableTerminated1Nov 30, 2023Registry ↗
Jun 1, 2022A Retrospective Analysis to Evaluate Long Term Outcomes of SCC Patients Previously Treated With Alp…
NCT05125354 · Squamous Cell Carcinoma, DaRT Treated Patients
DRTS
Alpha Tau Medical Ltd.
—Completed33Mar 6, 2022Registry ↗
Jun 1, 2022Feasibility Trial of Diffusing Alpha-emitter Radiation Therapy (DaRT) for Malignant Skin & Superfic…
NCT04377360 · Malignant Skin Tumor, Soft Tissue Tumor, Malignant
Diffusing Alpha-emitter Radiation Therapy
DRTS
Alpha Tau Medical Ltd.
Not applicableCompleted10Mar 28, 2022Registry ↗
Mar 10, 2021Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT)
NCT03353077 · Skin Squamous Cell Carcinoma
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
DRTS
Alpha Tau Medical Ltd.
Not applicableCompleted28Jul 14, 2019Registry ↗
Jan 13, 2021Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma
NCT03015883 · Squamous Cell Carcinoma
Diffusing Alpha Radiation Emitters Therapy (DaRT)
DRTS
Alpha Tau Medical Ltd.
Not applicableCompleted28Jun 1, 2019Registry ↗

29 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:42 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances